Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

5.63
+0.18003.30%
Post-market: 5.61-0.0200-0.36%19:30 EDT
Volume:1.01M
Turnover:5.69M
Market Cap:156.83M
PE:-3.61
High:5.77
Open:5.51
Low:5.50
Close:5.45
52wk High:8.74
52wk Low:3.71
Shares:27.86M
Float Shares:25.82M
Volume Ratio:1.42
T/O Rate:3.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.94
PE(LYR):-3.37

Loading ...

Nov 29, 2021

Major Issues Report

8-K - Current report
Nov 12, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2021

Major Issues Report

8-K - Current report
Sep 23, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Sep 10, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Aug 16, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 16, 2021

Major Issues Report

8-K - Current report
Jul 12, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jul 12, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jul 08, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 08, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 07, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 06, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 06, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jun 30, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jun 23, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jun 22, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jun 21, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Jun 14, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jun 14, 2021

Correspondence

CORRESP [Cover] - Correspondence